Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy

Critical Reviews in Immunology

Volumn 21, Issue 1-3, 2001, Pages 299-310

  Kawakami, K ^a   Kawakami, M ^a   Puri, R K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Clinical trial; cpIL4 PE; Immunotherapy; Preclinical development

Indexed keywords

CELL ADHESION MOLECULE; CHIMERIC PROTEIN; CIRCULAR PERMUTATED INTERLEUKIN 4 PSEUDOMONAS EXOTOXIN; CYTOTOXIN; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CELL SURFACE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DRUG TARGETING; EXPERIMENTAL NEOPLASM; GLIOBLASTOMA; HUMAN; IMMUNOREGULATION; KAPOSI SARCOMA; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE I; HUMANS; IMMUNOTOXINS; INTERLEUKIN-4; RECEPTORS, INTERLEUKIN-4; TISSUE DISTRIBUTION;

EID: 0034799739     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (74)

1. Identification of a T cell-derived B cell stimulatory factor distinct from IL-2
2. Interleukin-4: A prototypic immunoregulatory lymphokine
3. Interleukin-4 and cancer therapy
4. Structure and function of interleukin 4 and its receptors
5. Phase I evaluation of thrice daily intravenous bolus interleukin-4 in patients with refractory malignancy
6. Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections - A Phase I dose escalation toxicity trial
7. Recombinant human interleukin 4 (IL-4) administered by the intravenous and subcutaneous injections - A phase I toxicity study and pharmacokinetics analysis
8. + cell line (XS52) by IL-4, TNF-α, IL-1β, and agonistic anti-CD40 monoclonal antibody
9. IL-4 induces the intracellular expression of the alpha chain of the high-affinity receptor for IgE in in vitro-generated dendritic cells
10. + cells in cancer patients
11. Expression of high affinity IL4 receptors on murine sarcoma cells and receptor mediated cytotoxicity of tumor cells to chimeric protein between IL-4 and Pseudomonas extoxin
12. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4
13. Human basophils express interleukin-4 receptors
14. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin
15. Characterization of the human B cell stimulatory factor 1 receptor
16. Expression of high affinity receptors for murine interleukin 4 (BSF-1) on hematopoietic and nonhematopoietic cells
17. Detection of receptors for B cell stimulatory factor 1 (BSF 1): Presence of functional receptors on CBA/N splenic B cells
18. Interleukin 4 receptors on normal human B lymphocytes: Characterization and regulation
19. Interleukin-4 receptors on human blood mononuclear cells
20. Characterization of interleukin-4 receptors expressed on human renal cell carcinoma cells
21. Expression and function of high affinity interleukin-4 receptors on human melanoma, ovarian and breast carcinoma cells
22. Interleukin-4 receptor expression in vivo on human AIDS-related Kaposi's sarcoma
23. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenografted model
24. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo
25. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein
26. Inhibition of colon and breast carcinoma cell growth by interleukin-4
27. Head and neck cancers, but not benign lesions, express interleukin-4 receptors in situ
28. Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells
29. Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4
30. Interleukin-4 receptor expression and growth inhibition of gastric carcinoma by interleukin-4
31. Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo
32. Functional interleukin 4 receptor and interleukin 2 receptor common gamma-chain on human non-small cell lung cancers: Novel targets for immune therapy
33. Preclinical development of a recombinant toxin containing circularly permuted interleukin-4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma
34. Interleukin-13 receptor et chain: A novel tumor-associated transmembrane protein in primary explants of human malignant gliomas
35. Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily
36. Receptors for interleukin (IL)-4 do not associate with the common γ chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells
37. DNA cloning and characterization of the human interleukin-13 receptor α chain
38. Interleukin-2 receptor gamma chain: A functional component of the interleukin-4 receptor
39. c chain between receptors for IL-2 and IL-4
40. Intedeukln-2 receptor γ chain: A functional component of interleukin-7 receptor
41. Interaction of IL-2 receptor beta and gamma chain with JAK 1 and JAK 3: Implications for XSCID and XCID
42. Utilization of beta and gamma chains of the IL-2 receptor by novel cytokine IL-15
43. Receptor for interleukin 13: Interaction with interleukin 4 by a mechanism that does not involve the common γ chain shared by receptors for interleukins 2, 4, 7, 9, and 15
44. Structure of and signal transduction through interleukin 4 and interleukin 13 receptors
45. The interleukin-13 receptor structure differs on various cell types and may share more than one component with interleukin-4 receptor
46. Human ovarian carcinoma cell lines express IL-4 and IL-13 receptors: Comparison between IL-4 and IL-13 signaling
47. Interleukin-13 receptor α' chain but not α chain: A functional component of interleukin-4 receptor
48. Comparison of IL-13 and IL-4 induced signaling in EBV immortalized human B cells
49. Sharing of receptor subunits and signal transduction pathway between the IL-4 and IL-13 receptor system
50. c chain of the IL-2 receptor
51. Up-regulation of intracellular adhesion molecule-1 on human renal cell carcinoma cells by interleukin-4
52. Suramin blocks binding of interleukin-4 to its receptors and interleukin-4-induced mitogenic response
53. Transcriptional up-regulation of interleukin 4 receptors by human immunodeficiency virus type 1 tat gene
54. Redesigning nature's poisons to create antitumor agents
55. Recombinant toxins for cancer treatment
56. Recombinant toxins as novel therapeutic agents
57. Immunotoxins for the treatment of leukemia
58. Targeting diphtheria toxin to growth factor receptors
59. Immunotoxins for central nervous system malignancy
60. Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma
61. Immunotoxins in cancer therapy
62. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells
63. A circularly permuted recombinant interleukin 4 toxin with increased activity
64. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma
65. Cellular tumorigenicity in nude mice: Correlation with cell growth in semi-solid medium
66. Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate
67. Sensitization of cancer cells to interleukin 13-Pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor α chain
68. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy
69. A receptor binding domain of mouse interleukin-4 defined by a solid phase binding assay and in vitro mutagenesis
70. Clinical pathologic alterations associated with subcutaneous administration of recombinant interleukin-4 to cynomolgus monkeys
71. Preclinical evaluation of recombinant interleukin-4
72. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors
73. Pseudomonas exotoxin for therapy of gliomas
74. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma